Juniper Bio and Memorial Sloan Kettering partner on hypoxia imaging agent for oropharyngeal cancer

Juniper Biosciences, the Bridgewater, N.J.-based radiopharmaceutical developer, has entered a strategic licensing agreement with Memorial Sloan Kettering Cancer Center (MSK) to advance JBS-003 (18F-fluoromisonidazole), a hypoxia PET imaging tracer in Phase III development for HPV-positive oropharyngeal carcinoma. The JBS-003 partnership centers on translating MSK’s accumulated clinical data on F-MISO PET imaging into a defined FDA regulatory pathway, with Juniper targeting a filing window in late 2029. Financial terms were not disclosed, though MSK holds a financial interest in Juniper Biosciences, indicating an equity component to the arrangement.

Under the structure of the oncology imaging partnership, MSK contributes validated clinical data on the hypoxia diagnostic drug candidate, while Juniper provides radiopharmaceutical manufacturing capabilities and regulatory development infrastructure. The division of responsibilities positions MSK as the scientific and clinical anchor and Juniper as the commercialization-oriented party responsible for moving the asset toward regulatory submission.

JBS-003 is described in the announcement as a first-in-class hypoxia tracer in the US. The asset functions as a precision molecular imaging agent: administered prior to radiation planning, it maps oxygen-depleted regions within a tumor, identifying areas of hypoxia that are known to confer radioresistance. The clinical rationale is that patients whose tumors are confirmed as non-hypoxic by F-MISO PET imaging may be candidates for a substantially reduced radiation dose, while those with hypoxic tumors continue on the standard regimen.

The ongoing Phase III trial NCT06563479 is a randomized, double-blind study enrolling a planned 291 participants. Patients in the personalized arm receive an 18F-fluoromisonidazole scan at week two of treatment. Those returning a non-hypoxic result are eligible for a de-escalated 30 Gray radiation dose delivered over three weeks, compared to the standard 70 Gray regimen administered over seven weeks. Patients with hypoxic scan results continue on the standard protocol. The trial is expected to reach primary completion in early 2028.

The dose reduction under evaluation represents a 67% decrease in absorbed ionizing radiation for patients identified as non-hypoxic. According to Juniper, approximately 75% to 80% of patients with HPV-positive oropharyngeal carcinoma have non-hypoxic tumors, which the company cites as the basis for the potential scale of treatment de-escalation across the patient population. The current standard of care applies a uniform high-dose radiation regimen regardless of individual tumor biology, an approach that Juniper and MSK contend results in preventable morbidity, including osteoradionecrosis, significant weight loss requiring feeding tube intervention, and long-term quality-of-life impairment.

Nancy Lee, MD, Vice Chair of Experimental Therapeutics and Service Chief of Head and Neck Radiation Oncology at MSK, cited the combination of MSK’s clinical evidence base and Juniper’s regulatory translation capabilities as the rationale for the collaboration. Alex Agnoletto, CEO of Juniper Biosciences, described the imaging approach as enabling clinicians to maintain aggressive radiation control where tumor biology warrants it while reducing dose burden in patients with well-oxygenated tissue.

---

This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/